文献速递冠心病心力衰竭与心肌病

可溶性LOX-1与急性冠脉综合征患者预后相关

Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome.
PubMed 文献 · Heart · 2026-08-25

该研究前瞻性评估血浆可溶性LOX-1(sLOX-1)与急性冠脉综合征(ACS)患者心力衰竭(HF)、主要不良心血管事件(MACE)及冠状动脉和左心室功能不全的关联。两个队列分别纳入524例和363例ACS患者,并在体外研究LOX-1阻断的抗炎作用。结果显示,sLOX-1升高与HF、MACE及心脏和冠状动脉功能不全相关,提示LOX-1可能是改善ACS预后的潜在治疗靶点。

要点

  • 急性期sLOX-1升高与ACS后新发HF和MACE独立相关。
  • sLOX-1升高与左室射血分数降低及1年重构加速相关。
  • LOX-1阻断在体外可抑制ox-LDL诱导的内皮细胞活化。

核心结论

  • 基线及随访期间血浆sLOX-1升高与ACS患者新发HF、MACE及心脏和冠状动脉功能不全相关。
  • sLOX-1水平可能反映血管和免疫细胞上LOX-1表达强度,支持LOX-1作为改善ACS预后的潜在治疗靶点。

研究设计与样本

  • 前瞻性研究两个ACS患者队列:第一队列524例(瑞典马尔默Skåne大学医院冠脉监护病房急性期招募),第二队列363例(瑞典哥德堡Sahlgrenska大学医院接受急诊经皮介入治疗)。
  • 体外使用人脐静脉内皮细胞(HUVECs)研究LOX-1阻断的抗炎作用。

主要发现

  • 第一队列中,急性期sLOX-1与HF独立相关(每增加1-SD的HR=1.57,95%CI:1.10-2.23,p=0.012),与MACE独立相关(HR=1.36,95%CI:1.08-1.71,p=0.009),独立于心血管危险因素、血运重建和药物治疗。
  • 第一队列中,sLOX-1升高与ACS后1年超声心动图测量的左室射血分数降低和重构加速相关。
  • 第二队列中,sLOX-1与左前降支冠状动脉血流储备和左室收缩功能负相关,与ACS后4周和16周全身炎症和心脏负荷的可溶性标志物正相关。
  • 体外实验中,抗体介导的LOX-1阻断可防止氧化低密度脂蛋白诱导的HUVEC活化。

临床怎么用

  • 血浆sLOX-1或可用于ACS后HF和MACE的风险分层,但需进一步验证。
  • LOX-1阻断可能成为改善ACS患者预后的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The lectin-like oxidised low-density lipoprotein receptor-1 (LOX-1) mediates atherosclerotic plaque inflammation and vulnerability. On activation, LOX-1 sheds its extracellular domain into the circulation as soluble LOX-1 (sLOX-1). sLOX-1 is markedly elevated in patients with acute coronary syndrome (ACS). METHODS: We prospectively assessed the associations between plasma sLOX-1 and the development of heart failure (HF), major adverse cardiovascular events (MACE) and coronary and left ventricular (LV) dysfunction in two cohorts of patients with ACS. The first cohort comprised 524 patients recruited during the acute index event at the coronary care unit of Skåne University Hospital, Malmö, Sweden. The second cohort included 363 patients with ACS treated with acute percutaneous intervention at Sahlgrenska University Hospital, Gothenburg, Sweden. Additionally, we examined the anti-inflammatory effects of LOX-1 blockade in vitro using human umbilical vein endothelial cells (HUVECs). RESULTS: In the first cohort, acute-phase sLOX-1 was associated with incident HF and MACE independently of cardiovascular risk factors, revascularisation and medication (HR per 1-SD sLOX-1 increase: 1.57 (95% CI: 1.10 to 2.23; p=0.012) for HF and 1.36 (1.08 to 1.71; p=0.009) for MACE). Elevated sLOX-1 was also associated with lower LV ejection fraction and accelerated remodelling, as measured by echocardiography at 1-year post-ACS. In the second cohort, sLOX-1 was negatively associated with left anterior descending coronary artery flow reserve and LV systolic function, and positively correlated with soluble markers of systemic inflammation and cardiac overload at 4 and 16 weeks post-ACS. In vitro, antibody-mediated LOX-1 blockade prevented oxidised low-density lipoprotein-induced HUVEC activation. CONCLUSIONS: Elevated plasma sLOX-1 at baseline and during follow-up is associated with incident HF and MACE, as well as cardiac and coronary dysfunction in patients with ACS. As plasma sLOX-1 levels may reflect the intensity of LOX-1 expression on vascular and immune cells, these findings support LOX-1 as a potentially important therapeutic target to improve prognosis in patients with ACS.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Schiopu, Svedlund, Narasimhan, et al. Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome. Heart. 2026. PMID: 40957671. doi:10.1136/heartjnl-2025-326315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。